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As HIV-infected individuals age due to improved antire-
troviral therapy, they may be at increased risk for age-
related co-morbidities such as cardiovascular disease
(CVD). Increasing numbers of these individuals are initiat-
ing statins by meeting criteria for primary cardiovascular
disease prevention [1].
Previous guidelines for the general population had
recommended statin therapy based on 10-year cardiovas-
cular risk (CV risk) with goal LDL-cholesterol (LDL-C)
levels depending on the risk score. The latest guidelines
have changed to identify four statin-requiring risk groups.
They include: 1. Patients with known atherosclerotic cardi-
ovascular disease. 2. Individuals with LDL-C ≥ 190 mg/dL
(≥ 4.91 mmol/L). 3. Anyone age 40 to 75 with Type 1 or 2
diabetes mellitus (DM). 4. Individuals with a 10-year CV
risk ≥ 7.5%. Statin therapy is then considered moderate
intensity or high intensity when achieving a 30-50% reduc-
tion or > 50% reduction in LDL-C, respectively. The
guidelines define the intensity of therapy that applies [2].
In HIV infection, incident cardiovascular events are
higher than that of the general population [3-5]. Clinical
judgment must be brought into play when deciding
whether to follow the general population guidelines for
calculation of 10-year CV risk and whether to select a
lower risk value at which to start therapy. Also, there are
three calculators: 1. Framingham risk calculation. 2. Pooled
cohort risk calculation. 3. D*A*D risk calculation. To date,
management guidelines in HIV-infection are lacking.
Providers must also be cognizant of the interactions of
statins with protease-inhibitors and other drugs metabo-
lized by the cytochrome CYP 3A enzyme and adjust the
doses accordingly [6,7].
Finally, statins have recently been found to be asso-
ciated with incident (DM). In the general population the
benefits of statin therapy outweigh the risks of incident
DM [8-13]. A study in an HIV-infected population
demonstrated similar incidence of DM as compared to
studies in the general population [14].
Statin therapy reduces CVD events in all at risk
patients. Initiation of statin therapy in HIV-infection
requires additional clinical judgment due to the increase
risk of CVD events and drug interactions. The cardio-
vascular disease benefits of statins outweigh the risks of
incident DM.
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